Nanoparticle Artificial Antigen-Presenting Cells for NKT Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer and other disorders are limited in effectively generating and activating Natural Killer T (NKT) cells, which are crucial for immune responses, due to challenges in evading immune detection and destruction by cancer cells.
Innovation Solution
Development of artificial antigen-presenting cells (aAPCs) that activate and generate NKT cells by incorporating NKT cell activating ligands such as CD1d and co-stimulatory molecules like anti-CD28, using microparticles or nanoparticles, to stimulate NKT cells in vivo or ex vivo for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapy approaches are used to activate NKT cells, then immune response is stimulated, but cancer cells evade immune detection and destruction
Solution Approach 1:
The patent uses artificial antigen-presenting cells (aAPCs) as intermediaries to bridge the gap between NKT cells and cancer cells. The aAPCs are engineered to express CD1d molecules that present glycolipid antigens to NKT cells, while also expressing co-stimulatory molecules. This intermediary system overcomes cancer cell immune evasion by providing a controlled, optimized activation interface that cancer cells cannot easily bypass.
Solution Approach 2:
The invention modifies key parameters of antigen presentation by controlling the density and distribution of CD1d molecules and co-stimulatory ligands on aAPC surfaces. By optimizing these parameters, the system ensures sufficient NKT cell activation while maintaining specificity. The nanoparticle formulation also changes the physical parameters of antigen delivery, enabling enhanced cellular uptake and presentation efficiency.
2Productivity
If NKT cells are activated using traditional methods, then some immune response is generated, but the activation and expansion is insufficient for effective therapy
Solution Approach 1:
The patent combines multiple activation signals into a single aAPC platform. The nanoparticles simultaneously present glycolipid antigens via CD1d molecules and provide co-stimulatory signals through expressed ligands. This merging of Signal 1 (antigen recognition) and Signal 2 (co-stimulation) into one integrated system dramatically enhances NKT cell activation and expansion compared to traditional methods that may use separate components.
Solution Approach 2:
The aAPCs are constructed as composite nanoparticles combining multiple functional elements: CD1d molecules for antigen presentation, co-stimulatory ligands for Signal 2, and targeting moieties for specificity. This composite structure enables simultaneous delivery of multiple activation signals with optimized spatial arrangement, achieving superior NKT cell proliferation and functional activation.
3Adaptability or versatility
If non-specific immune activation is used, then broad immune response is stimulated, but specificity against tumor antigens is reduced
Solution Approach 1:
The patent applies local quality by engineering aAPCs with spatially organized functional domains. CD1d molecules presenting specific glycolipid antigens are positioned alongside co-stimulatory ligands in a controlled arrangement on the nanoparticle surface. This localized organization ensures that NKT cell activation occurs through specific antigen recognition rather than non-specific stimulation, maintaining both activation efficiency and antigen specificity.
Data Source
AI summary
The present invention relates to, in part, artificial antigen presenting cells that are useful in treating disease (including cancers) and have uses, for example, directly in vivo and/or in the expansion of a patients cells for re-introduction ex vivo.